Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00541411
Other study ID # RAC#2031-065
Secondary ID
Status Active, not recruiting
Phase N/A
First received October 9, 2007
Last updated April 16, 2012
Start date June 2003
Est. completion date June 2013

Study information

Verified date April 2012
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide combination chemotherapy in Ewing's Sarcoma


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with Ewing's Sarcoma

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vincristine, Actinomycin-D, Ifosfamide
Chemotherapy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy overall No
See also
  Status Clinical Trial Phase
Withdrawn NCT01734863 - Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Phase 3
Completed NCT01674101 - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy N/A
Completed NCT02736565 - Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT00563680 - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Phase 2
Completed NCT00987636 - Study in Localized and Disseminated Ewing Sarcoma Phase 3
Terminated NCT00038142 - Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients Phase 2
Completed NCT02890758 - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Phase 1
Completed NCT01583543 - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Phase 2
Terminated NCT01313884 - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma Phase 2
Completed NCT01696669 - Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Phase 2
Completed NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Phase 1
Terminated NCT00568464 - Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) Phase 2
Completed NCT00001686 - Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed NCT00492141 - Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Phase 1/Phase 2
Completed NCT02063022 - Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Phase 3
Completed NCT01598454 - Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Phase 1
Recruiting NCT03442465 - Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Completed NCT02511132 - A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Phase 2
Completed NCT00923650 - Informed Consent in Pediatric Cancer Trials N/A
Completed NCT01962103 - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Phase 1/Phase 2